lost in pennyland
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
perhaps. I hope they go ahead and sell all the way down to .0001. Put me down for 50,000,000 shares.
They designed the trial with the FDA. The p-value they were looking for is a golden ticket to approval.
Go ahead and keep dropping it for a while.
Almost makes you wonder if it's the brokerages doing the manipulation here. Either way, we're being given a golden opp. here.
it's been the case for a months (years?) with TDA. Not sure about the other brokerages.
I have to call this in to buy, but not to sell with TDA. Is that true of all the brokerages, or just TDA?
I think that may be part of the reason for the fall here. Easy to sell, harder to buy. But when the frenzy stops, this is going up.
The FDA bases approval on the P-value. Anything below .05 is considered approvable. .001 is an incredible P-value.
WOLVes unite! This is a steal guys. Get 'em while they're cheap.
Too late for that. I just loaded up some more.
Can you say gift? Thank you foolish sellers. Now give me some more at .05, or head back to .27.
I think we're all going to owe the dude who sold in the first 11 minutes yesterday a big thank you soon. Sometimes the market plays some silly tricks.
Yeah, I agree, I have a hard time believing that people would be selling on news of a partnership, unless it was a bad deal for BMOD. But I think Maria and John have shown themselves to be shrewd business people, so I don't think they would let that happen.
Nonetheless, we continue our pilgrimage back to our homeland of .05.
I was sitting on a triple two days ago. I have a feeling that my .09s will be in the red by Friday. But I agree, keep holding -this will reverse eventually.
Because the trial results came out today and they weren't as good as people expected. Had the specificity and sensitivity showed numbers above 90% as had been seen in previous studies, those same people would've probably been able to sell in the 40s today.
Such is the nature of biotech investing.
That kind of analytical technology alreadly exists. Biomoda will simply have to adapt cypath to the technology. The p-value was incredibly good. If FDA makes that metric the basis of their decision, this will be a slam-dunk approval.
The results were less than hoped for. The 90%-plus accuracy that we had seen in previous studies weren't achieved. Cypath still appears to be approvable, just not as clear-cut as the market was looking for.
That's true. What the FDA will want to see, though, is a test that can identify a range from no cancer to those with lung cancer. BMOD is going to have to be able to prove that cypath does this accurately.
It's important that they pick up on some cancers that current non-invasive methods are missing (sensitivity). But for this to become a standard screen paid for by insurance companies, it is equally important that the test does not have false positives (specificity).
I'm wondering if 58% specificity needs to be improved upon before the FDA will approve cypath. The FDA and the insurance companies won't want to approve a test that sends 42 cancer-free people out of every 100 positive tests to get a catscan unnecessarily.
What's curious to me is that Dr. Bauer states that the objective of the study was to determine if Cypath could differentiate between the high risk and the the cancer group.
Wouldn't it be more useful to determine if Cypath could differentiate between those with high risk vs. those that are at low risk? I'll try to call and clarify this.
I disagree bud. They lost this in this year's tourney but they have a great team coming back next year. It's Kinda like my favorite college player's team North Carolina.
North Carolina will be the favorite to win it next year unless Harrison Barnes goes pro. BMOD is on path to get approved down the road, if their star player - Cypath - continues to improve.
Looks like BMOD's price is going to be radioactive for a few days til the market decides where the new base is. A second PR by the company stating that they will begin Phase III next week (or soon) would be very helpful right now.
Anyone care to inquire and request with Maria?
Okay guys let's see that last push to the 30s. PUSHHHH!
That is amazing. You aren't going to find many companies like it out there. And the payoff is coming soon...
Thank you Rain. You piece together one hell of a compelling case for BMOD. Is that info from the 10K?
Your post leads me to another question that I hope you can answer. There is such a great case for investing in BMOD, so where is the venture capital?
A few years back, a story about oncology ran on NPR. When the top oncologists were asked what the next great breakthrough in cancer treatment would be, the consensus was - diagnostics.
So why haven't the expert investors invested heavily in BMOD already? Is BMOD holding out for a better deal to fill their coffers with?
If so, this is a VERY unique opportunity for penny investors.
I just read the 10K and found it to be quite bullish. Management sounds confident that the trials will be a success. A couple of things stood out to me as possible negatives:
1.The company has no science experts. They list advisors and partners that are MD's. This is definitely an unusual set up for a biotech. Are these advisors getting paid with money or shares? We've already seen one trial glitch with the positive control group. From a financial standpoint it's a plus to go as lean as possible, so maybe for shareholders it will save us in terms of less (perhaps a lot less) dilution.
2.The company's cash position is meager. Reading between the lines, I think the company believes that they will see substantial price appreciation over the coming year and will be able to raise sufficient cash to fund phase III and commercialization without substantial share dilution. Ideally the price will rise to a dollar on great phase II results and the beginning of phase III through 2011. Is the goal to be starting phase III by the end of 2011 or finishing phase III by the end of 2011? When are they hoping to reach commercialization?
Thank you for digging those up. I think we'll see excellent phase II results in a couple of weeks, the FDA will give the thumbs up for phase III, and then we'll see a steady rise in anticipation of positive phase III results and approval.
could you re-print the results of the previously completed studies?
Forming a nice new base here which will be short-lived with trial news on the way...
You ought to pitch this to allallan. He was a big force (along with his followers) behind the NNVC run. He's still a big believer in NNVC. I think he'd get behind this one too. BMOD has similar potential, but is way further along in trials.
Trading is so thin on WOLV. Any significant bullish news will push this to the .20s or 30s within a day or two.
Okay WOLV, all you have to do is provide the fuel with a bullish PR!
Love how thin this trades. It reminds me of NNVC's move in the fall of 2005. It started off around .10 like BMOD and then went on a six month run that reached $3.60.
I'm pretty sure NNVC has still never tested their nanotechnology on a single human. The OS of NNVC was 100 million with a float of 20 million, not too much different than BMOD's, although I forget what BMOD's float is right now.
Both NNVC have a potential billion dollar technology, but we're in a much better position here with BMOD because they're close to getting their technology approved (within a year?)
If the technology gains acceptance as a standard yearly (which would make sense especially for smokers) cancer screen, this will fly right by that $3.60 and keep going.
Great call on this one rain. I think you've found your pennies to dollars stock. What is your price target if, miracle of all miracles this becomes a standard cancer screen?
Guys sometimes the share price takes a while to get rolling. It's only been a few days. Everybody get the word out about this and people will eventually move to quality. Investment is all about risk/reward and we have this on our side at .06.
We're in the catbird seat here.
could be a beaut with a lotta luck. I like what I'm seeing so far.
added IRBS to the list of longshots.
starting to see some small ripples here...
I like the action we've been seeing here lately. This is setting up nicely at .005.
now you're reaching.
Think about it, though. If he is as flyersfan say he is, the deal will get solved. By flyers' own definition, the debenture issue will be resolved and the PRs will be flying soon - along with the share price.
Agree, it's time to get this show on the road. Clear up the financials and they'll make their money back and then some.
I like WOLVIE a lot still, even though it has been slow-going. I'd definitely take .12 by this time next year, though I'm strongly in favor of $1.20.:)
Yes, this definitely has never been an I-hub stock ... and that's probably a good thing.
Dub, if every penny stock doubled each year with a 1000% intra-year spike off of the low, we'd all be billionaires by now. You've done a great job of getting the word out about WOLV. I already decided that WOLV was worth an investment back in March, but after reading your posts for a while I decided to go heavy on it.
Thinking back on what happened last year from the .03 to .04 range in the spring, .06 is starting to look like a very solid investment idea. For everyone who might have been burned last year by buying in the teens or twenties, here's your second chance at cheap shares.
I owe a big thank you! also to Willy!
You're right Dub, it's not the company that has been over-promising the last eight months or so. And actually, I never said it was.
And I'll tell you what, if you keep over-promising like you did last year, I'll be able to retire before I'm 50. So thank you, WOLV was one of my best investments of 2010. Maybe the best, I haven't looked that closely. The price has doubled year over year, and I was able to trade the majority of my shares last year for a 325% gain.
That's why I'm still here. Keep it coming my man!